Diverse Approaches to Alzheimer's Therapies Continue to Show Progress at ICAD

There should be some excellent investment opportunities in the companies conducting these clinical trials.

You can get more detail about the stage of development and approach by following the link in this clip.

Feel free to email the article and discuss among friends and fellow investors.

clipped from alzheimersreadingroom.blogspot.com A lot of good and encouraging news continues to come out of this week's Alzheimer's Association International Conference on Alzheimer's Disease 2008. --18-Month Data from an Extension of a Pivotal Trial of Dimebon in Alzheimer's --First U.S. Double-Blind Phase II Clinical Trial of IVIg (Immunotherapy) in Alzheimer's --Phase II Immunotherapy Trial with LY2062430 in Mild to Moderate Alzheimer's --Antidementia Drugs Contribute to Longer Life in People with Alzheimer's